Labcorp
Our global life sciences company brings diagnostic testing & drug development together.
Alert:
Labcorp has multiple COVID-19 testing options. Learn more >>>
Anti-Leucine-Rich, Glioma-Inactivated Protein 1 (LGI1), Serum
CPT:
86255
Special Instructions
If reflex test is performed, additional charges/CPT code(s) may apply.
Related Documents
Specimen Requirements
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Gel-barrier tube, red-top tube, serum gel tube, serum transfer tube
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
CSF or plasma; contaminated, hemolyzed, or severely lipemic specimens
Test Details
Use
Leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis is a rare autoimmune voltage-gated potassium channel complex (VGKC) antibody-associated limbic encephalitis. Specifically, it is classified as an ant neuronal surface antigen- or ant synaptic protein-associated autoimmune encephalitis. In addition to the common symptoms of limbic encephalitis such as cognitive impairment, seizures, and psychiatric disorders, this disease is also associated with faciobrachial dystonic seizure (FBDA) and refractory hyponatremia. Unlike other limbic encephalirides, LGI1 antibody encephalitis is rarly accompanied by tumors and shows a good response to immunotherapy.
This test works as an aid in the diagnosis of LGI1 antibody disorders. This test is also useful in managing antibody-positive (LGI1) individual following immunotherapy and/or plasmapheresis.
This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.
Limitations
Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Immunofluorescence (IFA)
References
Bing-Lei W, Jia-Hua Z, Yan L, et al. Three cases of antibody-LGI1 limbic encephalitis and review of literature. Int J Neurosci. 2019 Jul;129(7):642-648.30112956
Michael S, Waters P, Irani SR. Stop testing for auto-antibodies to the VGKC-complex: only request LGI1 and CASPR2. Pract Neurol. 2020 Oct;20(5):377-384.32595134
van Sonderen A, Petit-Pedrol M, Dalmu J, Titulaer MJ. The value of LGI1, CASPR2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017 May;13(5):290-301.28418022
Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019 Oct;40(10):2017-2030.31161339
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf